Project Grant 2035827
Award Date 2/15/21
Completion Date 4/30/22
Dollars Obligated $256K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- Progenitor Inc. received a $255,750 Small Business Innovation Research Phase I Project Grant from the National Science Foundation to develop off-the-shelf immuno-compatible cell therapies. The grant was awarded on February 1, 2021 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) and will fund the project through October 31, 2022 at Progenitor's facilities in Emigration Canyon, Utah. The NSF TIP program seeks to advance science and engineering research leading to...
- Celldrop Inc. received a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant award from the National Science Foundation on May 1, 2021 to develop allogeneic stem cell delivery for efficacy-enhanced equine biotherapeutics. The award supports research and development activities at Celldrop's Laramie, Wyoming facility through November 30, 2022. The project aims to advance Celldrop's stem cell delivery platform technology under the NSF's Technology, Innovation, and...
- This $250,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant supports the development of artificial substrates for growing human stem cells suitable for clinical applications at Oakland University from March 2023 to February 2025. The goal is to accelerate the potential benefits of using human pluripotent stem cells and their derivatives for treating and curing diseases by producing a synthetic substrate that supports growth of human pluripotent stem cells...
- The National Science Foundation awarded Cytorecovery Inc. a $255,986 Small Business Technology Transfer Phase I Project Grant under the Engineering program (CFDA 47.041) on March 15, 2021. The grant funded the development of on-chip integration of sample preparation and monitoring capabilities with dielectrophoretic cell isolation techniques. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award...
- This SBIR Phase I project, funded by a $305,000 award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a microchip-based technology for complex, multidimensional cell reprogramming. The project seeks to create a miniaturized liquid and cell handling system that leverages acoustic-electric micro-vortices to precisely and sequentially deliver genetic molecules, making advanced cell engineering more accessible across...
- This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...
- Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...
- This National Science Foundation Project Grant of $100,000 supports research into polyelectrolyte multilayered surfaces for use in human mesenchymal stem/stromal cell manufacturing. The goal is to develop a scalable and controllable polymeric coating composed of natural polymers to improve the cell expansion process used in producing therapeutic human mesenchymal stromal cells. The coating is constructed via layer-by-layer assembly of collagen and heparin and has been shown to increase cell...
- This $500,000 Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) will support the University of Notre Dame's research exploring the differentiation of stem cells into patterned blood vessel networks using hybrid memristor technology. Over a four-year period from October 2022 to September 2026, the University will engineer the first autonomous hybrid memory resistor and cell culture device to control human pluripotent stem cell differentiation into...
- This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...